← Leaderboards
Allison C Chin
Geron Corporation
$0
Attributed
$0
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$2,282,939 · 3
By mechanism
U19$2,282,939 · 3
Top collaborators
No co-investigators on record.
Most similar at Geron Corporation
Same institution · by research overlap
- R L Tolman$0
- Calvin B Harley$48,000
Others in their field
Top investigators on “Drug Screening /Evaluation”
- Fred M Gordin · Social And Scientific Systems, Inc.$68,001,399
- John C S Breitner · Johns Hopkins University$33,065,187
- Philip J Disaia · University Of California Irvine$21,551,991
- George R Painter · Chimerix, Inc.$19,230,662
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Stephen J Durako · Westat, Inc.$15,048,684
Research focus
Drug Screening /EvaluationTelomeraseEnzyme InhibitorsAntineoplasticsDrug Discovery /IsolationCooperative StudyGenetic TranslationHigh Throughput TechnologyHuman TissueLeukemiaMethod DevelopmentModel Design /DevelopmentScid MouseTroglitazoneXenotransplantationCell LineCord BloodDisease /Disorder ModelDna Directed Dna PolymeraseDna Directed Rna Polymerase
Grant awards (10)
TELOMERASE: A MOLECULAR TARGET FOR CANCER THERAPY$248,642
U19 · FY2003 · CA
TELOMERASE: A MOLECULAR TARGET FOR CANCER THERAPY$796,189
U19 · FY2002 · CA
NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY$0
U19 · FY2002 · CA
ADAPTIVE IMMUNOTHERAPY WITH LONG CIRCULATING MACROMOLECULAR THERAPEUTICS$0
U19 · FY2002 · CA
TELOMERASE: A MOLECULAR TARGET FOR CANCER THERAPY$632,753
U19 · FY2001 · CA
ADAPTIVE IMMUNOTHERAPY WITH LONG CIRCULATING MACROMOLECULAR THERAPEUTICS$0
U19 · FY2001 · CA
NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY$0
U19 · FY2001 · CA
TELOMERASE--A MOLECULAR TARGET FOR CANCER THERAPY$605,355
U19 · FY2000 · CA
ADAPTIVE IMMUNOTHERAPY WITH LONG CIRCULATING MACROMOLECULAR THERAPEUTICS$0
U19 · FY2000 · CA
NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY$0
U19 · FY2000 · CA